CoChat

The DOI matches its Crossref record; 412 of the 418 references it cites were found in a registry or an index.

The Amyloid-β Pathway in Alzheimer’s Disease

Open access

Abstract

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for Aβ-targeting therapeutic strategies in development for the early treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01249-0

Cites

412 of 412 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Traditional neuropathological phases of amyloid-β deposition in Alzheimer’s disease dementia. Red areas in Phase 1 depicts the cortical regions with the initial accumulation of amyloid-β during the early pre-clinical stage. Continued deposition in the same areas are shown in darker colors in the subsequent stages, with the new areas showing amyloid-β in red in each phase. Neocortical regions with the early accumulation of amyloid-β in phase 1 include association cortices. Additional accumulation is seen in allocortical regions and midbrain (phases 2 and 3), with the cerebellum and brain stem having amyloid-β accumulation in late phase clinical stages. The change to darker shading indicates the continuous accumulation of Aβ. Adapted with permission from ref. [13].
Fig. 1 Traditional neuropathological phases of amyloid-β deposition in Alzheimer’s disease dementia. Red areas in Phase 1 depicts the cortical regions with the initial accumulation of amyloid-β during the early pre-clinical stage. Continued deposition in the same areas are shown in darker colors in the subsequent stages, with the new areas showing amyloid-β in red in each phase. Neocortical regions with the early accumulation of amyloid-β in phase 1 include association cortices. Additional accumulation is seen in allocortical regions and midbrain (phases 2 and 3), with the cerebellum and brain stem having amyloid-β accumulation in late phase clinical stages. The change to darker shading indicates the continuous accumulation of Aβ. Adapted with permission from ref. [13].CC BY · PubMed Central
Fig. 2 Hypothetical biomarker evidence-driven model of AD pathophysiology. Hypothetical model of dynamic biomarkers of the AD is expanded to explicate the preclinical phase. Aβ is identified by cerebrospinal fluid Aβ42 assay or PET amyloid imaging. Synaptic dysfunction evidenced by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed yellow line to indicate that synaptic dysfunction may be detectable in carriers of the ε4 allele of the apolipoprotein E gene before detectable Aβ deposition. Neuronal injury is evidenced by cerebrospinal fluid tau or phospho-tau, and brain structure is documented by structural magnetic resonance imaging. Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease stage (x-axis). The temporal trajectory of two key indicators used to stage the disease clinically, cognitive and behavioral measures, and clinical function are also illustrated. Neurofilament light chain (NfL) and neurogranin are newer and potentially more accurate markers of neuronal injury. Figure adapted with permission from ref. [391].
Fig. 2 Hypothetical biomarker evidence-driven model of AD pathophysiology. Hypothetical model of dynamic biomarkers of the AD is expanded to explicate the preclinical phase. Aβ is identified by cerebrospinal fluid Aβ42 assay or PET amyloid imaging. Synaptic dysfunction evidenced by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed yellow line to indicate that synaptic dysfunction may be detectable in carriers of the ε4 allele of the apolipoprotein E gene before detectable Aβ deposition. Neuronal injury is evidenced by cerebrospinal fluid tau or phospho-tau, and brain structure is documented by structural magnetic resonance imaging. Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease stage (x-axis). The temporal trajectory of two key indicators used to stage the disease clinically, cognitive and behavioral measures, and clinical function are also illustrated. Neurofilament light chain (NfL) and neurogranin are newer and potentially more accurate markers of neuronal injury. Figure adapted with permission from ref. [391].CC BY · PubMed Central
Fig. 3 Amyloidogenic vs non-amyloidogenic pathway. Amyloid Precursor Protein (APP) is a single transmembrane protein. For the non-amyloidogenic pathway (left), APP is cleaved by A Disintegrin And Metalloprotease (ADAM) family proteases to yield the membrane-tethered C83 fragment and extracellularly released soluble APP alpha (sAPPα). In the amyloidogenic pathway (right), APP is first cleaved by β-secretase (β-APP-cleaving enzyme-1 or BACE1). CTF-β fragment is subsequently cleaved by γ-secretase composed of Presenilin 1 or 2, Nicastrin, PEN2 and APH-1. This proteolytic processing releases amyloid-β into the extracellular space. APP intracellular domain (AICD) from the initial β-secretase cleavage is released into intracellular space. Adapted with permission from ref. [392].
Fig. 3 Amyloidogenic vs non-amyloidogenic pathway. Amyloid Precursor Protein (APP) is a single transmembrane protein. For the non-amyloidogenic pathway (left), APP is cleaved by A Disintegrin And Metalloprotease (ADAM) family proteases to yield the membrane-tethered C83 fragment and extracellularly released soluble APP alpha (sAPPα). In the amyloidogenic pathway (right), APP is first cleaved by β-secretase (β-APP-cleaving enzyme-1 or BACE1). CTF-β fragment is subsequently cleaved by γ-secretase composed of Presenilin 1 or 2, Nicastrin, PEN2 and APH-1. This proteolytic processing releases amyloid-β into the extracellular space. APP intracellular domain (AICD) from the initial β-secretase cleavage is released into intracellular space. Adapted with permission from ref. [392].CC BY · PubMed Central
Fig. 4 Amyloid-β aggregation species and evidence of reversible states: the amyloid-β cycle. Aggregation species of Aβ can exist as monomers, dimers, oligomers, protofibril, fibril and amyloid plaques. These species exist in steady state where one form can convert to another in a bidirectional manner. The species are characterized by aggregate size, conformation state and solubility, with fibril and amyloid plaque being insoluble. Adapted with permission from ref. [108].
Fig. 4 Amyloid-β aggregation species and evidence of reversible states: the amyloid-β cycle. Aggregation species of Aβ can exist as monomers, dimers, oligomers, protofibril, fibril and amyloid plaques. These species exist in steady state where one form can convert to another in a bidirectional manner. The species are characterized by aggregate size, conformation state and solubility, with fibril and amyloid plaque being insoluble. Adapted with permission from ref. [108].CC BY · PubMed Central
Fig. 5 The evidence-driven experimental model of Aβ-tau synergy. Accumulation of neurofibrillary tangles made up of tau (red) and amyloid plaques composed of amyloid-β (blue) coincides in the neocortical areas in the brain of Alzheimer’s disease subjects supporting amyloid-β dependent tau propagation across neocortical regions. Inter-neuronal spreading of tau (bottom) is enhanced in AD brains with both plaques and tangle build-up. Adapted with permission from ref. [221].
Fig. 5 The evidence-driven experimental model of Aβ-tau synergy. Accumulation of neurofibrillary tangles made up of tau (red) and amyloid plaques composed of amyloid-β (blue) coincides in the neocortical areas in the brain of Alzheimer’s disease subjects supporting amyloid-β dependent tau propagation across neocortical regions. Inter-neuronal spreading of tau (bottom) is enhanced in AD brains with both plaques and tangle build-up. Adapted with permission from ref. [221].CC BY · PubMed Central
Fig. 6 Techniques of in vivo Alzheimer’s disease amyloid-β pathway staging, along the clinical continuum, based on molecular imaging and innovative algorithms. Neocortical distribution of [18F]-florbetapir is shown in a composite representation according to Aβ stages. Early composite (positive in stage 1 in green; left), intermediate composite (positive in stage 2 in blue; middle) and late composite (positive in stage 3 in red; right) can allow global and regional assessment of amyloid plaque deposition. Adapted with permission from: ref. [393].
Fig. 6 Techniques of in vivo Alzheimer’s disease amyloid-β pathway staging, along the clinical continuum, based on molecular imaging and innovative algorithms. Neocortical distribution of [18F]-florbetapir is shown in a composite representation according to Aβ stages. Early composite (positive in stage 1 in green; left), intermediate composite (positive in stage 2 in blue; middle) and late composite (positive in stage 3 in red; right) can allow global and regional assessment of amyloid plaque deposition. Adapted with permission from: ref. [393].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 418 references

Research works printed but not linked: 1

  1. Yamashita K, Hasegawa T, Iino T, Miura M, Watanabe T, Watanabe S, et al. P075-prediction of amyloid pathology by the plasma Aβ(1-42)/Aβ(1-40) ratio measured with fully automated immunoassay system (HISCL™ SERIES). J Prev Alz Dis. 2019;6:S89.

Cited by

See all 1,952

Metadata

Authors
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A.
Affiliations
  • Eisai (United States) (US)
  • UK Dementia Research Institute (GB)
  • Sahlgrenska University Hospital (SE)
  • National University of Singapore (SG)
  • The University of Texas at San Antonio (US)
  • Hanyang University Seoul Hospital (KR)
  • The University of Melbourne (AU)
  • University of Southern California (US)
  • University of Cambridge (GB)
  • The University of Tokyo (JP)
  • Uppsala University (SE)
  • University of Nevada, Las Vegas (US)
Corresponding author
  • Hampel, Harald
  • Vergallo, Andrea
Venue
Molecular Psychiatry
Published
2021-08-30
Volume
26
Issue
10
Pages
5481-5503
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3198052269
Cited by
1,952
References
418
Citations by year
2026: 451 · 2025: 608 · 2024: 468 · 2023: 297 · 2022: 113 · 2021: 15
FWCI
30.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • National University of Singapore (submittedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Molecular Psychiatry
  • Apollo
Funders
Alzheimer’s Drug Discovery Foundation (RDAPB-201809-2016615)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, Alzheimer's disease, tau protein, neuroinflammation, neurodegeneration, synaptic failure, multimodal biomarkers, in vivo biomarkers, disease-modifying therapy, early treatment
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Amyloid-β Pathway in Alzheimer’s Disease. https://app.cochat.ai/papers/10.1038/s41380-021-01249-0
The paper
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A. (2021). The Amyloid-β Pathway in Alzheimer’s Disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01249-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.